We are a biopharmaceutical company using our proprietary Precision Timed Release TM (“PTR TM ”) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes.
Phase 3 · ActiveModality: small molecule (oral, PTR tablet)
Partnerships IQVIA: licensing and services master agreement (November 2025) for US commercialization of CTx-1301 pending FDA approval; Indegene: prior joint commercialization agreement replaced with master services agreement May 2025
Indications
ADHD (6 years and older)(Phase 3)
Status note NDA submitted July 31, 2025 under 505(b)(2) (reference: Focalin XR). FDA issued Complete Response Letter June 2, 2026 requesting additional CMC information; company working to support resubmission; funding through mid-2027 disclosed.
CTx-1302
Preclinical · ActiveModality: small molecule (oral, PTR tablet)
Partnerships not disclosed
Indications
ADHD(Preclinical)
Status note Planned Phase 1/2 bioavailability study in ADHD patients before pivotal Phase 3; timing dependent on additional capital.
CTx-2103
Preclinical · ActiveModality: small molecule (oral, PTR)
Target 5-HT1A
Partnerships not disclosed
Indications
Anxiety-related disorders(Preclinical)
Status note Buspirone candidate; pre-IND meeting held Q4 2023, 505(b)(2) pathway expected; additional capital required to continue development.
Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Specialist fund holders
Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
None of the tracked specialist funds reported a position in the latest 13F snapshot.
Latest news
Loading headlines…
Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 721 stocks.